Anticoagulation and Bleeding: A Pooled Analysis of Lung Cancer Trials of the NCIC Clinical Trials Group  by Le Maître, Aurélie et al.
ORIGINAL ARTICLE
Anticoagulation and Bleeding
A Pooled Analysis of Lung Cancer Trials of the NCIC
Clinical Trials Group
Aure´lie Le Maître, MSc,* Keyue Ding, PhD,* Frances A. Shepherd, MD, FRCPC,†
Natasha Leighl, MD, MMSc, FRCPC,† Andrew Arnold, MD, ECFMG, MRCP, FRCPC,‡
and Lesley Seymour, MD, PhD*
Background: Patients with cancer, including lung cancer are at an
increased risk for venous thromboembolism and frequently are
anticoagulated. Due to concerns of bleeding and drug-drug interac-
tions, many clinical trials suggest the use of low-molecular-weight
heparin (LMWH) rather than warfarin (coumadin) for patients
requiring anticoagulation. We sought to evaluate, in a retrospective
analysis, whether these recommendations were appropriate.
Material/Methods: A pooled analysis of three lung cancer trials
conducted by the NCIC Clinical Trials Group was performed to
evaluate the risk of bleeding in patients receiving warfarin or
LMWH; concomitant usage of nonsteroidal antinflammatories or
aspirin. The Mantel-Haentzel test stratified by treatment group was
used to analyze the prevalence of bleeding (all and grade 3)
according to LMWH, warfarin or nonsteroidal antiinflammatory
drugs usage. Logistic regression was used to adjust for baseline
characteristics including age, sex, performance status, creatinine,
platelets.
Results: Although bleeding was reported in a quarter of patients,
only 2% experienced severe bleeding, with rates similar across the
trials. In univariate analyses the risk of bleeding seemed higher with
LMWH or warfarin usage, history of bleeding, thrombocytopenia,
and increased age. However, in adjusted analyses only warfarin use
was a significant risk factor (p  0.073).
Conclusions: In this retrospective analysis, warfarin seemed to
increase the risk of bleeding in lung cancer patients enrolled in
clinical trials. Current recommendations in many clinical trials to
preferentially use LMWH seem appropriate.
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Cancer and its treatments are well-recognized risk fac-tors for venous thromboembolism (VTE). A large
population based, case control study1 showed that the risk
of VTE was increased sevenfold in patients with malig-
nancy, and that lung cancer had one of the highest inci-
dence rates. The National Hospital Discharge Survey2
revealed a VTE incidence of 2.1% among lung cancer
patients, compared with 1% in hospitalized patients with-
out cancer. More recently, Chew et al.3 found that the
1-year incidence of VTE in lung cancer patients was
significantly increased compared with the general popula-
tion (Standardized Incidence Ratio  21.2, 95% CI 20.4–
22.0). The risk of VTE seems to be higher still in patients
with lung cancer receiving chemotherapy.4
Long-term anticoagulation, usually with warfarin has
potential problems in this population. Both recurrent VTE
and bleeding during oral anticoagulant therapy are more
frequent in patients with cancer than in patients without
malignancy5,6 and drug-drug interactions frequently have
been described and may be more common with orally
administered molecularly targeted agents. Low-molecular
weight heparin (LMWH) may be a safer alternative to oral
anticoagulant therapy. A meta-analysis7 including noncancer
trials between 1994 and 2001 showed a reduction in the rate of
VTE recurrences and major bleeding complications in favor of
LMWH compared with oral anticoagulants although the differ-
ence was not significant. A more recent meta-analysis suggests
that LMWHmay be superior in terms of recurrence of VTE.8 In
addition, Meyer et al.9 showed that warfarin was associated with
a high bleeding rate in patients with VTE and cancer. In 2003,
the CLOT study (Randomized Comparison of Low-Molecular-
Weight Heparin versus Oral Anticoagulant Therapy for the Pre-
vention of Recurrent Venous Thromboembolism in Patients with
Cancer)10 revealed that dalteparin was more effective than an oral
anticoagulant in reducing the risk of recurrent thromboembolism
without increasing the risk of bleeding in patients with cancer.
We report here the results of a retrospective pooled
analysis of three lung cancer trials from the NCIC Clinical
Trials Group that investigates whether the prevalence of
bleeding was different according to anticoagulant treat-
ment received. In addition, the impact of nonsteroidal
antiinflammatory drugs and aspirin was examined.
*NCIC, Clinical Trials Group, Kingston; †Princess Margaret Hospital/
University Health Network, Toronto; and ‡Margaret and Charles Ju-
ravinski Cancer Centre, Hamilton, ON, Canada.
Disclosure: The authors declare no conflicts of interest.
Address for correspondence: Lesley Seymour, MD, PhD, 10 Stuart Street,
NCIC, Clinical Trials Group, Queen’s University, Kingston, ON, Canada
K7L 3N6. E-mail: lseymour@ctg.queensu.ca
Copyright © 2009 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/09/0405-0586
Journal of Thoracic Oncology • Volume 4, Number 5, May 2009586
METHODS
Studies Included
Three randomized controlled trials of the NCIC Clini-
cal Trials Group completed between 2000 and 2006 were
analyzed to assess the risk of bleeding according to antico-
agulant received. The treatment arms for each of the trials are
described in Table 1. All randomized patients were including,
irrespective of random assignment.
The BR.18 trial11 compared the matrix metalloprotein-
ase inhibitor (MMPI) BMS-275291 to placebo in 774 non-
small cell lung cancer (NSCLC) patients receiving first-line
paclitaxel plus carboplatin chemotherapy. The BR.20 trial12
included 107 patients and compared vandetanib to placebo in
small cell lung cancer patients who had achieved complete or
partial response to induction chemotherapy with or without
radiation therapy. The BR.21 trial13 compared the epidermal
growth factor receptor inhibitor erlotinib to placebo (2:1
randomization) in 731 NSCLC patients with cancer treated
after the failure of first-line or second-line chemotherapy. All
randomized patients (1612) are included in this study. All
three trials used Common Toxicity Criteria version two
(CTC) to categorize and grade toxicity, including laboratory
values. There were no limitations on concomitant anticoagu-
lants in BR.21 and BR.18, although BR.21 required close
monitoring for patients on warfarin, and suggested that
LMWH should be used preferentially. In BR.18, VTE was
reported in 7% in patients receiving chemotherapy alone and
in 9% of patients on the MMPI arm, although in BR.20 1
patient receiving placebo had VTE compared with three
vandetanib-treated patients. In BR.21, 3% of patients were
reported to have had VTE on study (same in both arms).
Concomitant Drugs
Concomitant medications taken at entry to the study and
during the study were recorded with onset and stop dates.
Reasons for usage were recorded in BR.18 only. LMWH,
warfarin, and nonsteroidal antiinflammatory drugs including
aspirin (NSAID) usage was summarized. As expected, some
patients used more than one category of these agents concomi-
tantly.
Outcome Measures
The primary study outcome was the occurrence of
bleeding after the usage (if used at or prior to randomization)
or initiation of the concomitant anticoagulant or NSAID.
Bleeding adverse events were included irrespective of cau-
sality to protocol therapy and included central nervous system
bleeding, melena or other gastro-intestinal bleeding, epi-
staxis, bleeding associated with surgery, hemoptysis, rectal
bleeding, petechiae/purpura, hemorrhage/bleeding, hematu-
ria, vaginal bleeding, hematemesis, and disseminated intra-
vascular coagulation.
Statistical Analysis
Comparisons of baseline and on-treatment characteris-
tics of patients in the three trials were performed to determine
whether the patient populations varied among the three trials.
The Mantel–Haenszel test stratified by treatment arm was
used to test the association between baseline and on-treatment
characteristics in the pooled database.
The 2 test was used to compare the occurrence of
bleeding according to baseline and on-treatment characteris-
tics (including anticoagulant and NSAID usage) of patients in
each trial and the Mantel–Haenszel test stratified by treatment
arm was used in the pooled database. The same analysis was
made to explore grade 3 or higher bleeding toxicities.
A logistic regression analysis was performed to explore
the influence of baseline and on-treatment characteristics on
the risk of bleeding in the pooled database. Interactions
between warfarin, LMWH and NSAIDs were introduced into
the model. The stepwise model-selection was used to select
the appropriate variables in the model.
RESULTS
Description of Baseline and on Treatment
Characteristics by Trial
Pretreatment and on-treatment patient characteristics
are presented in Table 2. As expected due to the differing
eligibility criteria of the three trials, there were more patients
with performance status 2 or 3 in the BR.21 trial, more
patients with abnormal creatinine in BR.20 and more patients
TABLE 1. Treatment Arms of the Trials Included
Trial Description Treatment Arm Sample Size
BR18, Leighl et al.10
Arm 1 Paclitaxel (200 mg/m2) plus Carboplatin (AUC 6 mg/ml-min) intravenously
every 21 d for up to 8 cycles  oral BMS-275291 (1200 mg) daily
387
Arm 2 Paclitaxel (200 mg/m2) plus Carboplatin (AUC 6 mg/ml-min) intravenously
every 21 d for up to 8 cycles  placebo (1200 mg) daily
387
BR20, Arnold et al.11
Arm 1 Vandetanib (300 mg/d) orally, maximum of 2 yr 54
Arm 2 Placebo (300 mg/d) orally, maximum of 2 yr 53
BR21, Shepherd et al.12
Arm 1 Erlotinib (150 mg/d) orally 243
Arm 2 Placebo (150 mg/d) orally 488
AUC, area under curve.
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with thrombocytopenia during treatment in BR.18, the only
chemotherapy trial. More patients on BR.18 received
NSAIDs than in the two others trials. The incidence of
hemorrhage of any grade or causality was lowest in the
placebo (BR21/20 and chemotherapy  MMPI arms, BR.18,
2–3%), intermediate with BR.21 (EGFRI, 6%), and highest
on the active arm of BR20 (vandetanib, 19%). The majority
of the events were mild.
TABLE 2. Patients Characteristics by Trial
BR18 (n  774) BR20 (n  107) BR21 (n  731)
CT
(n  387)
CT  MMPI
(n  387)
Placebo
(n  54)
Vandetanib
(n  53)
Placebo
(n 243)
Erlotinib
(n  488)
Baseline characteristics
Age
65 252 (65%) 251 (65%) 34 (63%) 43 (81%) 153 (63%) 299 (61%)
65 135 (35%) 136 (35%) 20 (37%) 10 (19%) 90 (37%) 189 (39%)
Sex
Male 283 (73%) 282 (73%) 31 (57%) 27 (51%) 160 (66%) 315 (65%)
Female 104 (27%) 105 (27%) 23 (43%) 26 (49%) 83 (34%) 173 (35%)
Performance status
0 114 (29%) 104 (27%) 20 (37%) 11 (21%) 34 (14%) 64 (13%)
1 229 (59%) 236 (61%) 29 (54%) 37 (70%) 132 (54%) 256 (52%)
2 or 3 44 (11%) 47 (12%) 5 (9%) 5 (9%) 77 (32%) 168 (34%)
Platelet
150 4 (1%) 9 (2%) 2 (4%) 1 (2%) 8 (3%) 18 (4%)
150 383 (99%) 378 (98%) 52 (96%) 52 (98%) 235 (97%) 470 (96%)
Creatinine
UNL 370 (96%) 375 (97%) 33 (62%) 47 (89%) 222 (92%) 442 (91%)
UNL 17 (4%) 12 (3%) 20 (38%) 6 (11%) 20 (8%) 42 (9%)
History of bleeding
No 387 (100%) 387 (100%) 53 (98%) 53 (100%) 243 (100%) 486 (100%)
Yes 0 (0%) 0 (0%) 1 (2%) 0 (0%) 0 (0%) 2 (0%)
LMWH
No 362 (94%) 357 (92%) 51 (94%) 51 (96%) 236 (97%) 474 (97%)
Yes 25 (6%) 30 (8%) 3 (6%) 2 (4%) 7 (3%) 14 (3%)
Warfarin
No 377 (97%) 377 (97%) 51 (94%) 49 (92%) 230 (95%) 458 (94%)
Yes 10 (3%) 10 (3%) 3 (6%) 4 (8%) 13 (5%) 30 (6%)
NSAID
No 282 (73%) 290 (75%) 46 (85%) 42 (79%) 179 (74%) 373 (76%)
Yes 105 (27%) 97 (25%) 8 (15%) 11 (21%) 64 (26%) 115 (24%)
On treatment characteristics (anticoagulants and NSAIDs at any time)
Minimum platelet
before bleeding
100 123 (32%) 94 (24%) 1 (2%) 3 (6%) 9 (4%) 12 (2%)
100 264 (68%) 293 (76%) 53 (98%) 50 (94%) 234 (96%) 475 (98%)
LMWH
No 302 (78%) 294 (76%) 49 (91%) 51 (96%) 220 (91%) 454 (93%)
Yes 85 (22%) 93 (24%) 5 (9%) 2 (4%) 23 (9%) 34 (7%)
Warfarin
No 359 (93%) 358 (93%) 51 (94%) 49 (92%) 228 (94%) 457 (94%)
Yes 28 (7%) 29 (7%) 3 (6%) 4 (8%) 15 (6%) 31 (6%)
NSAID
No 199 (51%) 193 (50%) 36 (67%) 37 (70%) 134 (55%) 284 (58%)
Yes 188 (49%) 194 (50%) 18 (33%) 16 (30%) 109 (45%) 204 (42%)
None of these drugs
No 239 (62%) 243 (63%) 23 (43%) 21 (40%) 124 (51%) 241 (49%)
Yes 148 (38%) 144 (37%) 31 (57%) 32 (60%) 119 (49%) 247 (51%)
NSAID, nonsteroidal antiinflammatory drugs; LMWH, Low-molecular weight heparin; UNL, upper limit of normal.
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TABLE 3. Relation Between Baseline Characteristics and Concomitant Drugs in the Pooled Database
LMWH Warfarin NSAID
No Yes p No Yes p No Yes p
Age
BR18 0.970 0.412
65 389 (77%) 114 (23%) 469 (93%) 34 (7%) 253 (50%) 250 (50%)
65 207 (76%) 64 (24%) 248 (92%) 23 (8%) 139 (51%) 132 (49%)
BR20 0.116
65 73 (95%) 4 (5%) 73 (95%) 4 (5%) 54 (70%) 23 (30%)
65 27 (90%) 3 (10%) 27 (90%) 3 (10%) 19 (63%) 11 (37%)
BR21
65 414 (92%) 38 (8%) 427 (94%) 25 (6%) 251 (56%) 201 (44%)
65 260 (93%) 19 (7%) 258 (92%) 21 (8%) 167 (60%) 112 (40%)
Sex
BR18 0.087 0.121 0.289
Male 438 (78%) 127 (22%) 526 (93%) 39 (7%) 289 (51%) 276 (49%)
Female 158 (76%) 51 (24%) 191 (91%) 18 (9%) 103 (49%) 106 (51%)
BR20
Male 54 (93%) 4 (7%) 54 (93%) 4 (7%) 41 (71%) 17 (29%)
Female 46 (94%) 3 (6%) 46 (94%) 3 (6%) 32 (65%) 17 (35%)
BR21
Male 446 (94%) 29 (6%) 450 (95%) 25 (5%) 277 (58%) 198 (42%)
Female 228 (89%) 28 (11%) 235 (92%) 21 (8%) 141 (55%) 115 (45%)
Performance
status
BR18 0.000 0.247 0.000
0 159 (73%) 59 (27%) 197 (90%) 21 (10%) 115 (53%) 103 (47%)
1 373 (80%) 92 (20%) 439 (94%) 26 (6%) 224 (48%) 241 (52%)
2 or 3 64 (70%) 27 (30%) 81 (89%) 10 (11%) 53 (58%) 38 (42%)
BR20
0 30 (97%) 1 (3%) 30 (97%) 1 (3%) 23 (74%) 8 (26%)
1 62 (94%) 4 (6%) 62 (94%) 4 (6%) 44 (67%) 22 (33%)
2 or 3 8 (80%) 2 (20%) 8 (80%) 2 (20%) 6 (60%) 4 (40%)
BR21
0 92 (94%) 6 (6%) 93 (95%) 5 (5%) 50 (51%) 48 (49%)
1 371 (96%) 17 (4%) 363 (94%) 25 (6%) 204 (53%) 184 (47%)
2 or 3 211 (86%) 34 (14%) 229 (93%) 16 (7%) 164 (67%) 81 (33%)
Platelet
BR18 0.405 0.008 0.084
150 8 (62%) 5 (38%) 11 (85%) 2 (15%) 5 (38%) 8 (62%)
150 588 (77%) 173 (23%) 706 (93%) 55 (7%) 387 (51%) 374 (49%)
BR20
150 2 (67%) 1 (33%) 3 (100%) 0 (0%) 1 (33%) 2 (67%)
150 98 (94%) 6 (6%) 97 (93%) 7 (7%) 72 (69%) 32 (31%)
BR21
150 25 (96%) 1 (4%) 21 (81%) 5 (19%) 12 (46%) 14 (54%)
150 649 (92%) 56 (8%) 664 (94%) 41 (6%) 406 (58%) 299 (42%)
Creatinine
BR18 0.153 0.012 0.263
UNL 570 (77%) 175 (23%) 689 (92%) 56 (8%) 376 (50%) 369 (50%)
UNL 26 (90%) 3 (10%) 28 (97%) 1 (3%) 16 (55%) 13 (45%)
BR20
UNL 73 (91%) 7 (9%) 76 (95%) 4 (5%) 56 (70%) 24 (30%)
UNL 26 (100%) 0 (0%) 23 (88%) 3 (12%) 16 (62%) 10 (38%)
BR21
UNL 613 (92%) 51 (8%) 628 (95%) 36 (5%) 385 (58%) 279 (42%)
UNL 56 (90%) 6 (10%) 52 (84%) 10 (16%) 30 (48%) 32 (52%)
(Continued)
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Relationship Between Baseline Characteristics
and Concomitant Drugs
Table 3 describes the relation between anticoagulants
and NSAIDs taken during study treatment and baseline pa-
tient characteristics. One hundred fifty two patients (9.4%)
had more than one drug (14% in BR.18, 3% in BR.20 and 6%
in BR.21). Patients with a poorer performance status (2, 3)
were more likely to be treated with LMWH. Few patients had
platelet counts under 150  109/liter and the observation that
warfarin or NSAID usage seemed more frequent in these
patients is difficult to interpret. Patients with an elevated
creatinine were more likely to receive warfarin compared
with those with a normal creatinine. The mean duration of
treatment with anticoagulants, (although on protocol only, as
data on concomitant medications were not collected thereaf-
ter), was shorter than treatment with NSAIDs (up to 4 months
versus 7 months). These differences in duration of therapy are
likely due to protocol requirements for discontinuation of
protocol therapy with severe adverse effects such as VTE.
The most common reason for usage of anticoagulants was for
the treatment, prevention and or prophylaxis of venous or
arterial thromboembolism, and usage for central line prophy-
laxis was not reported.
Univariate Analysis of Bleeding
Overall, 25% of patients had bleeding adverse events
reported at any time in the three trials: 23% in BR.18, 23% in
BR.20, and 29% in BR.21 (Table 4). Older patients (65
years) were more likely to have bleeding of all grades (p 
0.054), but there was no apparent increase in severe bleeding
(grade 3), although a history of bleeding predicted for an
increased risk of severe bleeding (p  0.003). There was a
trend (p  0.075) for an increased risk of severe bleeding
with platelet counts 150  109/liter at entry. Gender,
performance status, and creatinine were not predictive.
There was a significantly increased risk of bleeding of
all grades and severe bleeding with on-treatment thrombocy-
topenia (100 109/liter p 0.013 and 0.001, respectively)
and warfarin usage (p  0.005 and 0.0002, respectively;
Table 5). LMWH usage was associated with increased severe
bleeding (p  0.003) although NSAID usage did not result in
an increased risk of bleeding.
Multivariate Analysis of Bleeding Toxicities
The risk of bleeding was assessed after adjusting for
baseline characteristics, treatment arm, and anticoagulants or
NSAIDs. The only significant covariate that affected the risk
of bleeding was warfarin, with an odds ratio of 1.7 (95% CI
1.2–2.6) (Table 6a). Interaction between warfarin and
LMWH or NSAID did not meet the statistical criterion for
entry into the model.
As patients commonly were exposed to more than one
drug of interest, we also performed three different models
with only one concomitant drug as the covariate in each
model. The model with only LMWH and the model with only
an NSAID as the concomitant drug did not show an excess
risk of bleeding with these drugs. The only significant co-
variate in these two models was age with an odds ratio of 1.3
(p value  0.058) for patients more than 65 years of age. In
contrast, in the model with only warfarin as the concomitant
drug, there was a significant association between the risk of
bleeding (odds ratio  1.7, 95% CI 1.2–2.6, p value 
0.007). Once again, the only other covariate selected in the
model was age (odds ratio  1.2, p value  0.07).We also
performed an analysis to check potential drug and drug
interaction on grade 3 or higher bleeding toxicities, and found
that the use of LMWH only (OR  8.1, 95% C.I. 3.3 – 20.3,
p  0.0001) or warfarin only (OR  4.4, 95% C.I. 1.9 –
10.3, p  0.0005) increased the risk of grade 3 or higher
bleeding, while the alternative use of LMWH and warfarin
decreased the risk (OR 0.05, 95% C.I. 0.01 – 0.49, p 
0.01) (Table 6b).
DISCUSSION
In patients with cancer, the risk of VTE is higher
than in the general population, and this risk seems to
increase further with treatment, especially chemotherapy
and hormonal therapy. Many patients included in clinical
TABLE 3. (Continued)
LMWH Warfarin NSAID
No Yes p No Yes p No Yes p
History of
bleeding
BR18 0.616 0.659 0.324
No 596 (77%) 178 (23%) 717 (93%) 57 (7%) 392 (51%) 382 (49%)
Yes 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
BR20
No 99 (93%) 7 (7%) 99 (93%) 7 (7%) 72 (68%) 34 (32%)
Yes 1 (100%) 0 (0%) 1 (100%) 0 (0%) 1 (100%) 0 (0%)
BR21
No 672 (92%) 57 (8%) 683 (94%) 46 (6%) 418 (57%) 311 (43%)
Yes 2 (100%) 0 (0%) 2 (100%) 0 (0%) 0 (0%) 2 (100%)
p value of a Mantel–Haenszel test stratified by treatment arm.
NSAID, nonsteroidal antiinflammatory drugs; LMWH, Low-molecular weight heparin; UNL, upper limit of normal.
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TABLE 4. Relation Between Bleeding Toxicities and Baseline Characteristics of Patients
in the Pooled Database
Bleeding Toxicity Bleeding Toxicity Grade 3 or Higher
No (n  1202) Yes (n  410) p No (n  1575) Yes (n  37) p
Age
BR18 0.054 0.274
65 394 (78.3%) 109 (21.7%) 496 (98.6%) 7 (1.4%)
65 204 (75.3%) 67 (24.7%) 268 (98.9%) 3 (1.1%)
BR20
65 63 (81.8%) 14 (18.2%) 77 (100%) 0 (0.0%)
65 19 (63.3%) 11 (36.7%) 29 (96.7%) 1 (3.3%)
BR21
65 330 (73.0%) 122 (27.0%) 439 (97.1%) 13 (2.9%)
65 192 (68.8%) 87 (31.2%) 266 (95.3%) 13 (4.7%)
Sex
BR18 0.206 0.423
Male 431 (76.3%) 134 (23.7%) 558 (98.8%) 7 (1.2%)
Female 167 (79.9%) 42 (20.1%) 206 (98.6%) 3 (1.4%)
BR20
Male 46 (79.3%) 12 (20.7%) 57 (98.3%) 1 (1.7%)
Female 36 (73.5%) 13 (26.5%) 49 (100%) 0 (0.0%)
BR21
Male 333 (70.1%) 142 (29.9%) 456 (96.0%) 19 (4.0%)
Female 189 (73.8%) 67 (26.2%) 249 (97.3%) 7 (2.7%)
Performance
status
BR18 0.601 0.471
0 179 (82.1%) 39 (17.9%) 216 (99%) 2 (1%)
1 343 (73.8%) 122 (26.2%) 459 (99%) 6 (1%)
2 or 3 76 (83.5%) 15 (16.5%) 89 (98%) 2 (2%)
BR20
0 26 (83.9%) 5 (16.1%) 31 (100%) 0 (0.0%)
1 52 (78.8%) 14 (21.2%) 65 (98.5%) 1 (1.5%)
2 or 3 4 (40.0%) 6 (60.0%) 10 (100%) 0 (0.0%)
BR21
0 64 (65.3%) 34 (34.7%) 95 (96.9%) 3 (3.1%)
1 286 (73.7%) 102 (26.3%) 376 (96.9%) 12 (3.1%)
2 or 3 172 (70.2%) 73 (29.8%) 234 (95.5%) 11 (4.5%)
Platelet
BR18 0.767 0.075
150 8 (61.5%) 5 (38.5%) 12 (92.3%) 1 (7.7%)
150 590 (77.5%) 171 (22.5%) 752 (98.8%) 9 (1.2%)
BR20
150 3 (100%) 0 (0.0%) 3 (100%) 0 (0.0%)
150 79 (76.0%) 25 (24.0%) 103 (99.0%) 1 (1.0%)
BR21
150 19 (73.1%) 7 (26.9%) 24 (92.3%) 2 (7.7%)
150 503 (71.3%) 202 (28.7%) 681 (96.6%) 24 (3.4%)
Creatinine
BR18 0.973 0.983
UNL 576 (77.3%) 169 (22.7%) 736 (98.8%) 9 (1.2%)
UNL 22 (75.9%) 7 (24.1%) 28 (96.6%) 1 (3.4%)
BR20
UNL 59 (73.8%) 21 (26.3%) 79 (98.8%) 1 (1.3%)
UNL 22 (84.6%) 4 (15.4%) 26 (100%) 0 (0.0%)
(Continued)
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TABLE 4. (Continued)
Bleeding Toxicity Bleeding Toxicity Grade 3 or Higher
No (n  1202) Yes (n  410) p No (n  1575) Yes (n  37) p
BR21
UNL 477 (71.8%) 187 (28.2%) 640 (96.4%) 24 (3.6%)
UNL 42 (67.7%) 20 (32.3%) 60 (96.8%) 2 (3.2%)
History of
bleeding
BR18 0.156 0.003
No 598 (77.3%) 176 (22.7%) 764 (98.7%) 10 (1.3%)
Yes 0 (0%) 0 (0%) 0 (0%) 0 (0%)
BR20
No 82 (77.4%) 24 (22.6%) 105 (99.1%) 1 (0.9%)
Yes 0 (0.0%) 1 (100%) 1 (100%) 0 (0.0%)
BR21
No 521 (71.5%) 208 (28.5%) 704 (96.6%) 25 (3.4%)
Yes 1 (50.0%) 1 (50.0%) 1 (50.0%) 1 (50.0%)
p value of a Mantel–Haenszel test stratified by treatment arm.
UNL, upper limit of normal.
TABLE 5. Relation Between Bleeding Toxicities and on Treatment Characteristics of Patients in
the Pooled Database
Bleeding Toxicity Bleeding Toxicity Grade 3 or Higher
No (n  1202) Yes (n  410) p No (n  1575) Yes (n  37) p
Minimum platelet
before bleeding
BR18 0.013 0.001
100 185 (85.3%) 32 (14.7%) 213 (98.2%) 4 (1.8%)
100 413 (74.1%) 144 (25.9%) 551 (98.9%) 6 (1.1%)
BR20
100 3 (75.0%) 1 (25.0%) 3 (75.0%) 1 (25.0%)
100 79 (76.7%) 24 (23.3%) 103 (100%) 0 (0.0%)
BR21
100 12 (57.1%) 9 (42.9%) 17 (81.0%) 4 (19.0%)
100 510 (71.9%) 199 (28.1%) 687 (96.9%) 22 (3.1%)
LMWH
BR18 0.637 0.003
No 460 (77.2%) 136 (22.8%) 591 (99.2%) 5 (0.8%)
Yes 138 (77.5%) 40 (22.5%) 173 (97.2%) 5 (2.8%)
BR20
No 80 (80.0%) 20 (20.0%) 100 (100%) 0 (0.0%)
Yes 2 (28.6%) 5 (71.4%) 6 (85.7%) 1 (14.3%)
BR21
No 481 (71.4%) 193 (28.6%) 652 (96.7%) 22 (3.3%)
Yes 41 (71.9%) 16 (28.1%) 53 (93.0%) 4 (7.0%)
Warfarin
BR18 0.005 0.0002
No 563 (78.5%) 154 (21.5%) 709 (98.9%) 8 (1.1%)
Yes 35 (61.4%) 22 (38.6%) 55 (96.5%) 2 (3.5%)
BR20
No 78 (78.0%) 22 (22.0%) 99 (99.0%) 1 (1.0%)
Yes 4 (57.1%) 3 (42.9%) 7 (100%) 0 (0.0%)
(Continued)
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trials have smoking related cancers such as lung cancer,
and thus are more likely to have comorbid conditions
which may further increase the risk of both venous and
arterial thomboembolism.
Anticoagulants are thus commonly required in patients
with cancer, including lung cancer, but may increase the risk
of bleeding, especially when used in combination with che-
motherapeutic agents that may themselves increase the risk of
hemorrhage due to thrombocytopenia. More recently, some
molecularly targeted agents such as the angiogenesis inhibi-
tors have been shown to be associated with an increased risk
of bleeding and even fatal hemorrhage due to their direct
vascular effects.14 The oral receptor tyrosine kinase inhibitors
of the epidermal growth factor receptor may also increase the
risk of bleeding when used concomitantly with warfarin,
which is highly protein bound and thus commonly cited in
drug-drug interactions. Finally, the concomitant use of anti-
coagulants and corticosteroids that are frequently prescribed
for cancer patients for hypersensitivity or emesis prophylaxis
may increase the risk of gastrointestinal bleeding.
Many clinical trial protocols, particularly those trials
evaluating orally administered novel agents exclude patients
taking anticoagulants agents, because of fears of bleeding and
or drug-drug interactions. Even in clinical trials where anti-
coagulation is permissible at entry or on study, treatment may
be restricted to LMWH.
Our study suggests that warfarin usage significantly
increases the risk of bleeding, while NSAIDs and LMWH do
not. These results are consistent with results from other
studies.8,10 Interestingly, in univariate analyses, increased
age, low platelet counts (at entry or on treatment), and a prior
history of bleeding were also associated with an increased
risk of bleeding.
Our study has a number of limitations. The three trials
included a heterogeneous group of patients, including both
NSCLC patients (two trials) and small cell lung cancer
patients (one trial), as well as patients receiving therapy in
different settings (first-line, second- and third-line therapy).
However, it should be noted that all trials were palliative in
nature and included patients with relapsed or refractory dis-
ease. Furthermore, the trials tested different therapeutic mo-
dalities (chemotherapy, EGFRI, and MMPIs). As expected,
the incidences of VTE were also different among the trials,
with the highest incidence in BR.18, suggesting that both the
underlying cancer and type of anticancer therapy may in-
crease the risk of VTE. However, there were no significant
differences in the incidence of VTE between arms of each
trial. Another limitation of our study is that many patients
took combinations of anticoagulants and NSAIDs - in BR.18
for example, 49% of patients taking LMWH also took
NSAIDs. However we performed additional analyses to cor-
rect for this. Finally, although we collected data on concom-
TABLE 5. (Continued)
Bleeding Toxicity Bleeding Toxicity Grade 3 or Higher
No (n  1202) Yes (n  410) p No (n  1575) Yes (n  37) p
BR21
No 491 (71.7%) 194 (28.3%) 665 (97.1%) 20 (2.9%)
Yes 31 (67.4%) 15 (32.6%) 40 (87.0%) 6 (13.0%)
NSAID
BR18 0.813 0.646
No 307 (78.3%) 85 (21.7%) 384 (98.0%) 8 (2.0%)
Yes 291 (76.2%) 91 (23.8%) 380 (99.5%) 2 (0.5%)
BR20
No 57 (78.1%) 16 (21.9%) 73 (100%) 0 (0.0%)
Yes 25 (73.5%) 9 (26.5%) 33 (97.1%) 1 (2.9%)
BR21
No 295 (70.6%) 123 (29.4%) 404 (96.7%) 14 (3.3%)
Yes 227 (72.5%) 86 (27.5%) 301 (96.2%) 12 (3.8%)
None of these
drugs
BR18 0.914 0.032
No 371 (77.0%) 111 (23.0%) 474 (98.3%) 8 (1.7%)
Yes 227 (77.7%) 65 (22.3%) 290 (99.3%) 2 (0.7%)
BR20
No 31 (70.5%) 13 (29.5%) 43 (97.7%) 1 (2.3%)
Yes 51 (81.0%) 12 (19.0%) 63 (100%) 0 (0.0%)
BR21
No 264 (72.3%) 101 (27.7%) 348 (95.3%) 17 (4.7%)
Yes 258 (70.5%) 108 (29.5%) 357 (97.5%) 9 (2.5%)
p value of a Mantel–Haenszel test stratified by treatment arm.
NSAID, nonsteroidal antiinflammatory drugs; LMWH, low-molecular weight heparin.
Journal of Thoracic Oncology • Volume 4, Number 5, May 2009 Anticoagulation and Bleeding
Copyright © 2009 by the International Association for the Study of Lung Cancer 593
itant anticoagulants and NSAID usage, including the ratio-
nale for usage, we did not collect information on dosage, and
cannot definitively define the number of patients who may
have been receiving nontherapeutic doses of the agents for
line or port prophylaxis. Despite these confounding factors,
we believe the results provide information useful to research-
ers defining protocol parameters regarding anticoagulant and
NSAID usage.
In conclusion, based on this retrospective analysis of
three randomized trials of lung cancer, concomitant warfarin
usage should be avoided. For clinical trials, concomitant
LMWH usage seems acceptable, although consideration may
be given to exclusion of patients requiring LMWH with risk
factors such as age 65 or a history of bleeding, from trials
testing agents with a significant risk of bleeding (such as
angiogenesis inhibitors).
ACKNOWLEDGMENTS
This study was supported by the Canadian Cancer
Society.
REFERENCES
1. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, pro-
thrombotic mutations, and the risk of venous thrombosis. JAMA 2005;
293:715–722.
2. Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE.
Incidence of venous thromboembolism in patients hospitalized with
cancer. Am J Med 2006;119:60–68.
3. Chew HK, Davies AM, Wun T, Harvey D, Zhou H, White RH. The
incidence of venous thromboembolism among patients with primary
lung cancer. J Thromb Haemost 2008;6:601–608.
4. Shepherd F, Hasan B, Hicks L, et al. Venous thromboembolism and
non-small cell lung cancer: a pooled analysis of National Cancer Insti-
tute of Canada Clinical Trials Group trials. Eur J Caner 2007;5(Suppl):
361.
5. Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Bu¨ller HR.
Incidence of recurrent thromboembolic and bleeding complications
among patients with venous thromboembolism in relation to both ma-
lignancy and achieved international normalized ratio: a retrospective
analysis. J Clin Oncol 2000;18:3078–3083.
6. Prandoni P, Lensing A, Piccioli A, et al. Recurrent venous thromboem-
bolism and bleeding complications during anticoagulant treatment in
patients with cancer and venous thrombosis. Blood 2002;100:3484–
3488.
7. Iorio A, Guercini F, Pini M. Low-molecular-weight heparin for the
long-term treatment of symptomatic venous thromboembolism: meta
analysis of the randomized comparisons with oral anticoagulants.
J Thromb Haemost 2003;1:1906–1913.
8. Akl E, Barba M, Rohilla S, et al. Low-molecular-weight heparins are
superior to vitamin K antagonists for the long term treatment of venous
thromboembolism in patients with cancer: a cochrane systematic review.
J Exp Clin Cancer Res [serial online] 2008;27:21. Available from:
www.jeccr.com. Accessed August 15, 2008.
9. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low molecular-
weight heparin and warfarin for the secondary prevention of venous
thromboembolism in patients with cancer. Arch Int Med 2002;162:
1729–1735.
10. Lee AYY, Levine MN, Baker RI, et al. Low-molecular-weight heparin
versus a coumarin for the prevention of recurrent venous thromboem-
bolism in patients with cancer. New Engl J Med 2003;349:146–153.
11. Leighl NB, Paz-Ares L, Douillard JY, et al. Randomized phase III study
of matrix metalloproteinase inhibitor BMS-275291 in combination with
paclitaxel and carboplatin in advanced non–small-cell lung cancer:
National Cancer Institute of Canada–Clinical Trials Group Study BR.
18. J Clin Oncol 2005;23:2831–2839.
12. Arnold AM, Seymour L, Smylie M, et al. Phase II study of vandetanib
or placebo in small-cell lung cancer patients after complete or partial
response to induction chemotherapy with or without radiation therapy:
National Cancer Institute of Canada Clinical Trials Group Study BR. 20.
J Clin Oncol 2007;25:4278–4284.
13. Shepherd FA, Pereira JR, Ciuleanu T, et al. Erlotinib in previously
treated non–small-cell lung cancer. N Engl J Med 2005;353:123–132.
14. Crabb SJ, Patsios D, Sauerbrei E, et al. Tumor cavitation: impact on
objective response evaluation in trials of angiogenesis inhibitors in
non-small cell lung cancer. J Clin Oncol 2009;27:404–410
TABLE 6a. Result of the Logistic Regression to Predict
Bleeding Toxicity
Odds Ratio for
Bleeding 95% Confidence Interval p
Age
65 1 0.0683
65 1.24 0.98 1.57
Warfarin
No 1 0.0073
Yes 1.75 1.16 2.63
TABLE 6b. Result of the Logistic Regression to Predict
Bleeding Toxicity Grade 3 or Higher
LMWH without record of Warfarin use
No 1 0.0001
Yes 8.12 3.25 20.30
Warfarin without record of LMWH use
No 1 0.0005
Yes 4.44 1.92 10.27
Alternative use of LMWH and Warfarin
No 1 0.0102
Yes 0.05 0.01 0.49
LMWH, low-molecular weight heparin.
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